RAPT Therapeutics Inc
RAPT
View Detailed Chart
58.020USD
0.0000.00%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
1.32BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
+0.07%
6 Months
+119.94%
Year to Date
+71.30%
1 Year
+412.54%
View Detailed Chart
TradingKey Stock Score of RAPT Therapeutics Inc
Currency: USD Updated: 2026-03-02Key Insights
RAPT Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 174 out of 389 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 53.89.In the medium term, the stock price is expected to trend up.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
RAPT Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
RAPT Therapeutics Inc Highlights
StrengthsRisks
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -4.99, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 18.77M shares, increasing 0.67% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 25.18K shares of this stock.
Analyst Rating
Based on
8
analysts
Hold
Current Rating
52.714
Target Price
-9.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
RAPT Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
RAPT Therapeutics Inc Info
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Ticker SymbolRAPT
CompanyRAPT Therapeutics Inc
CEOWong (Brian)
Websitehttps://rapt.com/
Related Instruments
-2.09%
-1.92%
+0.51%
+2.74%
+0.59%
-0.81%
-1.02%
-1.24%
-0.39%
-1.92%
-0.99%
+0.34%
-0.19%
-1.50%
-4.56%
0.00%
-0.54%
-2.51%
-2.81%
-0.83%Popular Symbols
248.800
-4.090 (-1.62%)
167.520
-3.720 (-2.17%)
66947.620
+956.860 (+1.45%)
275.340
+1.990 (+0.73%)
2020.470
+36.930 (+1.86%)
361.830
-10.280 (-2.76%)
4492.520
+112.460 (+2.57%)
100.609
+7.287 (+7.81%)
1.151
-0.002 (-0.17%)
160.252
+0.465 (+0.29%)
